DSpace logo

Please use this identifier to cite or link to this item: http://142.54.178.187:9060/xmlui/handle/123456789/14412
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAHMAD, MAHMOOD-
dc.contributor.authorAHMAD, MANSOOR-
dc.contributor.authorHASAN, RUQAIYA-
dc.contributor.authorQURESHI, ANILA-
dc.contributor.authorAHMED, ZULFIQAR-
dc.date.accessioned2022-12-01T07:59:58Z-
dc.date.available2022-12-01T07:59:58Z-
dc.date.issued2006-01-10-
dc.identifier.citationAhmed, M., Ahmad, M., Hasan, R., Qureshi, A., & Ahmed, Z. (2006). The effects of mefenamic acid on hematocrit of the lizard, Uromastix hardwickii. Pakistan Journal of Pharmaceutical Sciences, 19(1), 48-51.en_US
dc.identifier.issn1011-601X-
dc.identifier.urihttp://142.54.178.187:9060/xmlui/handle/123456789/14412-
dc.description.abstractMefenamic acid is an analgesic, antipyretic and anti-inflammatory agent. In addition induces several hematological disturbances. Present study was conducted to determine the alterations in blood PCV of the lizard Uromastix hardwickii after the administration of 7.1 mg / ml; 10.5 mg / ml and 14.0 mg / ml mefenamic acid per individual per day for 12 days to 3 test groups. The mean values of PCV were 15.5 ± 0.81%, 14.5 ± 0.25% and 12.0 ± 0.25% for 3 test groups respectively in comparison to 23.5 ± 0.40% for control. Thus a significant dose dependant reduction in mean PCV per cent following the administration of mefenamic acid for 12 days indicates the extra vascular hemolysis due to destructive change in the red cell membrane through autoantibody mechanism.en_US
dc.language.isoenen_US
dc.publisherKarachi: Faculty of Pharmacy & Pharmaceutical Sciences, Karachien_US
dc.subjectPCVen_US
dc.subjectmefenamic aciden_US
dc.subjecthemolytic anemiaen_US
dc.titleTHE EFFECTS OF MEFENAMIC ACID ON HEMATOCRIT OF THE LIZARD, UROMASTIX HARDWICKIIen_US
dc.typeArticleen_US
Appears in Collections:2006,Part-1

Files in This Item:
File Description SizeFormat 
Paper-10.htm143 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.